Read our latest eMag
Read Now

Abingdon: Evotec expands further at Milton Park

By Dan Teuton
11 September 2020

Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft, making it one of the largest occupiers on the Park.

Evotec has had a presence in Milton Park ever since the company’s merger with Oxford Asymmetry International plc back in 2000. Oxford Asymmetry International had been based at Milton Park since 1989 in various guises and started in one of the original ex-MOD depot buildings.

Evotec’s latest letting for expansion space, which totals 16,823 sq ft at 90 Park Drive, has meant that it is now one of the largest occupiers at Milton Park alongside other companies such as Immunocore and Adaptimmune, which also started life at Milton Park in the old white buildings as University of Oxford spin-outs.

Christophe Muller, PhD, head of Evotec’s Milton Park site and EVP global head of business development, said: “Milton Park is an integral part of Evotec’s history and more than ever its future. The current expansion has been driven by an increased demand of our high-end drug discovery services, specifically in the areas of biological and protein sciences. The additional footprint, in bespoke facilities on Milton Park, as well as the recruitment of scientific experts, are also part of our plans to develop a fully integrated platform and centre of excellence for structure-based drug discovery in the UK.”

Philip Campbell, commercial director, MEPC commercial director, Milton Park said: “We congratulate Evotec on their impressive and continued expansion. What started as an Oxford University spin-out 30 years ago in a small depot has grown to become one of our largest occupiers employing approximately 600 people, as well as many others around the world. They are a great success story and we are really proud to be able to support them in their continued quest for drug discovery alliances and innovation across many disease areas which have significant impacts for people across the globe.”

From left: Christophe Muller and Philip Campbell

Related topics